Viking Therapeutics, Inc. (0VQA.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 3.97B |
| Enterprise Value | 3.8B |
| P/E Ratio | -6.81 |
| PEG Ratio | 0.08 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 9.01 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -6.7 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -1.02 |
| Return On Equity | -0.95 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -431,000 |
| EBITDA | -392.91M |
| Net Income | -359.64M |
| Diluted EPS | -3.19 |
| Total Cash | 501.66M |
| Total Cash/Share | 4.33 |
| Total Debt | 4.09M |
| Total Debt/Equity | 0.01 |
| Current Ratio | 4.72 |
| Book Value Per Share | 3.52 |
| 52-Week Change | -4.16 |
| 52-Week High | 99.3 |
| 52-Week Low | 8.79 |
| Moving Average 50 Days | 38.31 |
| Moving Average 200 Days | 21.29 |
| Average Volume | 10,491 |
| Shares Outstanding | 116.65M |
| % Held by Institutions | N/A |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |